Active	Status	Sponsor type	Region	Phase	Filter
8 Active 6 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
acazicolcept (ALPN-101) / AbbVie
NCT04835441 / 2020-004047-86: ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus	Completed	2	76	Europe, US, RoW	ALPN-101, Placebo	Alpine Immune Sciences, Inc.	Systemic Lupus Erythematosus	07/24	07/24
davoceticept (ALPN-202) / Alpine Immune Sci
NEON-2, NCT04920383: ALPN-202 With PD-1 Inhibition in Advanced Malignancies	Terminated	1	29	US	ALPN-202, pembrolizumab KEYTRUDA®	Alpine Immune Sciences, Inc., Merck Sharp & Dohme LLC	Advanced Solid Tumor, Lymphoma	11/22	02/23
NEON-1, NCT04186637: An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies	Terminated	1	62	US, RoW	ALPN-202	Alpine Immune Sciences, Inc.	Advanced Solid Tumor, Lymphoma	11/22	02/23
povetacicept (ALPN-303) / Vertex
NCT06564142: Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)	Recruiting	3	480	Europe, Canada, Japan, US, RoW	Povetacicept, ALPN-303, Placebo (matched to Povetacicept)	Alpine Immune Sciences Inc, A Subsidiary of Vertex	Immunoglobulin A Nephropathy	09/28	09/28
RUBY-3, NCT05732402: An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases	Active, not recruiting	1/2	72	US, RoW	Povetacicept, ALPN-303	Alpine Immune Sciences, Inc.	Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	01/26	01/26
RUBY-4, NCT05757570: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias	Active, not recruiting	1/2	30	Europe, Canada, US, RoW	povetacicept, ALPN-303	Alpine Immune Sciences, Inc.	Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease	07/26	07/26
NCT05034484: A Study of ALPN-303 in Adult Healthy Volunteers	Completed	1	72	RoW	ALPN-303, Placebo	Alpine Immune Sciences, Inc.	Healthy Volunteers	02/23	02/23
NCT07010406: A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations	Recruiting	1	136	US	Povetacicept	Vertex Pharmaceuticals Incorporated	Healthy Volunteers	08/25	08/25
vIgD Fc fusions targeting TIGIT/ PD-1 therapeutic / Alpine Immune Sci
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
acazicolcept (ALPN-101) / AbbVie
NCT04835441 / 2020-004047-86: ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus	Completed	2	76	Europe, US, RoW	ALPN-101, Placebo	Alpine Immune Sciences, Inc.	Systemic Lupus Erythematosus	07/24	07/24
davoceticept (ALPN-202) / Alpine Immune Sci
NEON-2, NCT04920383: ALPN-202 With PD-1 Inhibition in Advanced Malignancies	Terminated	1	29	US	ALPN-202, pembrolizumab KEYTRUDA®	Alpine Immune Sciences, Inc., Merck Sharp & Dohme LLC	Advanced Solid Tumor, Lymphoma	11/22	02/23
NEON-1, NCT04186637: An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies	Terminated	1	62	US, RoW	ALPN-202	Alpine Immune Sciences, Inc.	Advanced Solid Tumor, Lymphoma	11/22	02/23
povetacicept (ALPN-303) / Vertex
NCT06564142: Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)	Recruiting	3	480	Europe, Canada, Japan, US, RoW	Povetacicept, ALPN-303, Placebo (matched to Povetacicept)	Alpine Immune Sciences Inc, A Subsidiary of Vertex	Immunoglobulin A Nephropathy	09/28	09/28
RUBY-3, NCT05732402: An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases	Active, not recruiting	1/2	72	US, RoW	Povetacicept, ALPN-303	Alpine Immune Sciences, Inc.	Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	01/26	01/26
RUBY-4, NCT05757570: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias	Active, not recruiting	1/2	30	Europe, Canada, US, RoW	povetacicept, ALPN-303	Alpine Immune Sciences, Inc.	Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease	07/26	07/26
NCT05034484: A Study of ALPN-303 in Adult Healthy Volunteers	Completed	1	72	RoW	ALPN-303, Placebo	Alpine Immune Sciences, Inc.	Healthy Volunteers	02/23	02/23
NCT07010406: A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations	Recruiting	1	136	US	Povetacicept	Vertex Pharmaceuticals Incorporated	Healthy Volunteers	08/25	08/25
vIgD Fc fusions targeting TIGIT/ PD-1 therapeutic / Alpine Immune Sci
No trials found